Beta Bionics, Inc. Common Stock (BBNX)

• Market cap: $549M
• 1 day: -6.56%
• 5 days: -6.91%
• 1 month: -33.70%
• 3 months: 16.13%
• 6 months: -46.38%
• Year to date: -46.38%
• 1 year: -46.38%
• 5 years: -46.38%
• 10 years: -46.38%
• Sector: Healthcare
• Industry: Medical Devices

About: Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company product includes the iLet Bionic Pancreas (iLet). The Company operates as a single segment, focused on the development, manufacture and sale of the iLet.

Employees: 354

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

97.61% more ownership

Funds ownership: 0% [Q4 2024] → 97.61% (+97.61%) [Q1 2025]

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $16 26% upside
• Avg. target: $23 82% upside
• High target: $30 137% upside

4 analyst ratings

• positive: 3 75%
• neutral: 1 25%
• negative: 0 0%

Truist Securities Richard Newitter	105% upside $26	Buy Initiated	16 Jun 2025
Lake Street Frank Takkinen	137% upside $30	Buy Assumed	12 Jun 2025
Goldman Sachs David Roman	26% upside $16	Neutral Initiated	30 May 2025
Wolfe Research Mike Polark	58% upside $20	Outperform Initiated	30 May 2025